About Keros Therapeutics Inc
Keros Therapeutics (NASDAQ:KROS) is a biotechnology company focused on the development of innovative treatments for hematological and musculoskeletal disorders with high unmet medical needs. Through its pioneering research in transforming growth factor-beta (TGF-beta) family proteins, Keros aims to address diseases characterized by low blood cell counts, bone disorders, and muscular dystrophies. Their portfolio includes flagship projects such as KER-050 for the treatment of anemia and thrombocytopenia, and KER-047 designed to target fibrodysplasia ossificans progressiva and anemia of chronic disease. The company's objective is to leverage its deep understanding of TGF-beta protein mechanisms to advance a pipeline of novel therapeutics that can significantly improve patient outcomes and quality of life.
Snapshot
Operations
Products and/or services of Keros Therapeutics Inc
- Development of KER-050 for treating myelodysplastic syndromes and myelofibrosis, focusing on hematopoiesis enhancement.
- Exploring KER-047 for treating anemia of chronic disease and iron homeostasis disorders, aimed at improving patients' quality of life.
- Advancement of KER-012 for treating pulmonary arterial hypertension and certain types of heart failure, focusing on cardiovascular disease management.
- Innovative approaches in treating bone disorders and hematological conditions, leveraging proprietary technology for novel therapeutics.
- Collaboration with pharmaceutical companies for the development and commercialization of therapies in bone disease and hematologic disorders.
- Continuous research and development efforts aimed at expanding the pipeline with therapies targeting rare diseases and complex conditions.
Keros Therapeutics Inc executive team
- Dr. Jasbir S. Seehra Ph.D.President, CEO & Director
- Mr. Keith C. Regnante MBAChief Financial Officer
- Ms. Esther Cho J.D.Senior VP, General Counsel & Secretary
- Dr. Lorena Lerner Ph.D.Chief Scientific Officer